As of 2026-06-15, the Intrinsic Value of Rubius Therapeutics Inc (RUBY) is -14.47 USD. This RUBY valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.08 USD, the upside of Rubius Therapeutics Inc is -17,533.68%.
Based on its market price of 0.08 USD and our intrinsic valuation, Rubius Therapeutics Inc (RUBY) is overvalued by 17,533.68%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -14.47 - -14.47 | -14.47 | -17,533.68% |
| P/E | (54.41) - (62.80) | (59.33) | -71578.0% |
| DDM - Stable | (17.34) - (51.27) | (34.30) | -41427.9% |
| DDM - Multi | (13.93) - (34.06) | (20.01) | -24203.8% |
| Market Cap (mil) | 5.15 |
| Beta | 4.04 |
| Outstanding shares (mil) | 62.08 |
| Enterprise Value (mil) | -9.75 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.74% |
| Cost of Debt | 5.00% |
| WACC | 7.21% |